News NICE will only fund Opdivo in PD-L1 lung cancer patients Pharma must apply for Cancer Drugs Funding in restricted population - NICE
News NICE rejects Keytruda in lung cancer, points to price and da... Cancer immunotherapy too expensive.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
